Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer [Yahoo! Finance]
Lucid Diagnostics Inc. (LUCD)
Company Research
Source: Yahoo! Finance
NEW YORK Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard ® Esophageal DNA test for the diagnosis of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) on samples collected non-endoscopically using Lucid's EsoCheck ® Esophageal Cell Collection Device . The manuscript, entitled Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheck ® , a Non-Endoscopic Esophageal Cell Collection Device , has been published in the peer-reviewed journal Diagnostics , and is currently available via open access online. "This analytical validation study strongly complements EsoGuard's extensive peer-reviewed, pu
Show less
Read more
Impact Snapshot
Event Time:
LUCD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUCD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUCD alerts
High impacting Lucid Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
LUCD
News
- Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Ascendiant Capital Markets from $7.50 to $7.25. They now have a "buy" rating on the stock.MarketBeat
- Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressPR Newswire
- Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthPR Newswire
LUCD
Sec Filings
- 8/12/24 - Form 10-Q
- 8/12/24 - Form 8-K
- 7/24/24 - Form 8-K
- LUCD's page on the SEC website